Title
Brandname clearance limit for drug products
Law
Bfad (doh) Memorandum Circular 16-a
Decision Date
Jul 15, 1994
The BFAD (DOH) Memorandum Circular 16-A, issued on July 15, 1994, mandates that applications for brandname clearance of a drug or pharmaceutical specialty may only propose five names, streamlining the evaluation process by disallowing further assessment of names if one has already been approved.

Evaluation and Approval Process

  • The BFAD will evaluate the proposed brandnames submitted in the application.
  • If one brandname among the five proposed has already been cleared and approved by the BFAD, the evaluation of any remaining brandnames in the same application will be discontinued.
  • Only the approved brandname will be cleared for use, ensuring efficiency in processing applications.

Purpose and Implementation

  • The regulation aims to streamline and facilitate the evaluation process for brandname clearance applications.
  • It seeks to prevent unnecessary administrative workload and duplication of effort in the evaluation of multiple brandnames for the same drug.
  • This policy applies to all companies seeking brandname clearance for drugs or pharmaceutical specialties.

Effective Date and Authority

  • The memorandum circular was adopted on July 15, 1994.
  • It was issued under the authority of the Director of the Bureau of Food and Drugs, reflecting official guidance to all concerned stakeholders.

Analyze Cases Smarter, Faster
Jur helps you analyze cases smarter to comprehend faster, building context before diving into full texts. AI-powered analysis, always verify critical details.